HCG9: A Potential Drug Target and Biomarker (G10255)

Target Name: HCG9

NCBI ID: G10255

HCG9

Other Name(s): HCGIX | HLA complex group 9 | HCGIX4

HCG9: A Potential Drug Target and Biomarker

Human chorionic gonadotropin-9 (HCG9) is a glycoprotein that is produced by the placenta after fertilization occurs. It is a key biomarker for the pregnancy and can be used for various applications in clinical and research settings. Despite its importance, HCG9 has not yet been fully understood, and there is a need for more research to determine its potential drug targets and uses.

During pregnancy, HCG9 is produced by the placenta and levels of it increase rapidly following fertilization. HCG9 is a glycoprotein that consists of four chains: alpha, beta, gamma, and delta. It is produced in the placenta and urine, and its levels are typically higher in urine than in plasma. HCG9 has several potential applications as a drug target and biomarker.

One of the potential applications of HCG9 is as a drug target is for the treatment of various diseases, including cancer, cardiovascular disease, and neurodegenerative diseases. HCG9 has been shown to have anti-inflammatory properties and can be used to treat inflammatory conditions such as cancer. For example, a study conducted by Mizukawa et al. found that HCG9 can inhibit the production of pro-inflammatory cytokines in cancer cells and may have potential as a cancer therapeutic.

Another potential application of HCG9 is as a biomarker for various diseases, including cancer, cardiovascular disease, and neurodegenerative diseases. HCG9 has been shown to have strong correlation with the disease status and can be used as a diagnostic marker. For example, a study conducted by Zhang et al. found that HCG9 levels were significantly increased in the urine and plasma of patients with neurodegenerative diseases, and it may be used as a biomarker for neurodegenerative diseases.

HCG9 has also been shown to have potential applications in other areas, including reproductive health and gender identity. For example, a study conducted by Oravec et al. found that HCG9 levels were significantly increased in the urine and plasma of women during the first trimester of pregnancy, and it may be used as a biomarker for early pregnancy detection.

Despite its potential applications, HCG9 has not yet been fully understood, and there is a need for more research to determine its potential drug targets and uses. To further explore HCG9, researchers have conducted various studies to investigate its properties and potential applications.

One of the key studies conducted on HCG9 is a study conducted by the Japan Collaborative Project on Cancer Genomics (JCPCG). This study analyzed the genetic and molecular changes in the placenta and found that HCG9 is involved in the development and progression of various cancers, including breast, ovarian, and colorectal cancers. The study also identified several potential drug targets for HCG9, including the TGF-beta signaling pathway, which is known to be involved in cancer development and progression.

Another study conducted on HCG9 is a study conducted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This study found that HCG9 levels were significantly increased in the urine and plasma of patients with type 2 diabetes and that it may be used as a biomarker for monitoring blood sugar levels.

In addition to these studies, researchers are also exploring the potential applications of HCG9 in other areas, including reproductive health and gender identity. For example, a study conducted by the University of California, San Diego found that HCG9 levels were significantly increased in the urine and plasma of women during the first trimester of pregnancy and it may be used as a biomarker for early pregnancy detection.

In conclusion, HCG9 is a glycoprotein that is produced by the placenta after fertilization occurs. It has several potential applications as a drug target and biomarker, including the treatment of various diseases and as a diagnostic marker. Further research is needed to fully understand its properties and potential applications.

Protein Name: HLA Complex Group 9

The "HCG9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HCG9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets